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Abstract
Background:TopoisomeraseIIiscriticalforDNAreplication,transcriptionandchromosomesegregationandisawellvalidated
target of anti-neoplastic drugs including the anthracyclines and epipodophyllotoxins. However, these drugs are limited by
common tumor resistance mechanisms and side-effect profiles. Novel topoisomerase II-targeting agents may benefit patients
who prove resistant to currently available topoisomerase II-targeting drugs or encounter unacceptable toxicities. Voreloxin is
an anticancer quinolone derivative, a chemical scaffold not used previously for cancer treatment. Voreloxin is completing
Phase 2 clinical trials in acute myeloid leukemia and platinum-resistant ovarian cancer. This study defined voreloxin’s
anticancer mechanism of action as a critical component of rational clinical development informed by translational research.
Methods/Principal Findings: Biochemical and cell-based studies established that voreloxin intercalates DNA and poisons
topoisomerase II, causing DNA double-strand breaks, G2 arrest, and apoptosis. Voreloxin is differentiated both structurally
and mechanistically from other topoisomerase II poisons currently in use as chemotherapeutics. In cell-based studies,
voreloxin poisoned topoisomerase II and caused dose-dependent, site-selective DNA fragmentation analogous to that of
quinolone antibacterials in prokaryotes; in contrast etoposide, the nonintercalating epipodophyllotoxin topoisomerase II
poison, caused extensive DNA fragmentation. Etoposide’s activity was highly dependent on topoisomerase II while
voreloxin and the intercalating anthracycline topoisomerase II poison, doxorubicin, had comparable dependence on this
enzyme for inducing G2 arrest. Mechanistic interrogation with voreloxin analogs revealed that intercalation is required for
voreloxin’s activity; a nonintercalating analog did not inhibit proliferation or induce G2 arrest, while an analog with
enhanced intercalation was 9.5-fold more potent.
Conclusions/Significance: As a first-in-class anticancer quinolone derivative, voreloxin is a toposiomerase II-targeting agent
with a unique mechanistic signature. A detailed understanding of voreloxin’s molecular mechanism, in combination with its
evolving clinical profile, may advance our understanding of structure-activity relationships to develop safer and more
effective topoisomerase II-targeted therapies for the treatment of cancer.
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Introduction
Type II topoisomerases are essential for the survival of
eukaryotic cells [1,2,3,4,5]. These enzymes maintain DNA
topology, disentangling DNA that becomes knotted, under- or
over-wound in the process of replication, and are required to
maintain correct chromosome condensation, decondensation, and
segregation. Topoisomerase II acts by passing an intact DNA
double helix through another double helix that has been cleaved
by the enzyme, requiring a complex conformational change in the
enzyme that is fueled by ATP hydrolysis [1,3,4,6]. Following DNA
strand passage, topoisomerase II religates the cleaved strand.
Vertebrate cells encode two isoforms of topoisomerase II, a and b,
[1,3,4,5] which perform functions encompassing replication,
transcription and DNA repair (reviewed in [5]). Topoisomerase
IIa has been studied most extensively. This isoform is associated
with replication and is essential for chromosomal segregation.
Consistent with these functions its expression peaks at G2/M
phase of the cell cycle [1,3,5,7,8].
Topoisomerase II is well validated as a target of antineoplastic
drugs that poison the enzyme [3,9,10,11]. Poisons act by
increasing the concentration of the covalent topoisomerase II-
PLoS ONE | www.plosone.org 1 April 2010 | Volume 5 | Issue 4 | e10186cleaved DNA reaction intermediate (i.e. cleavage complex),
converting the transient DNA double-strand breaks (DSB) into
permanent lesions, with catastrophic impact in replicating cells
[3,10]. Topoisomerase II poisoning may result by direct
interaction of the drug with the enzyme, or by alterations in
DNA structure [3,9,10,11]. The widely used epipodophyllotoxins,
etoposide and teniposide, do not intercalate DNA, but poison
topoisomerase II by inhibiting religation [3,9,10]. Intercalative
topoisomerase II-poisoning drugs include the anthracyclines
doxorubicin (Figure 1), daunorubicin and idarubicin, and the
anthracenedione, mitoxantrone. The anthracyclines and mitoxan-
trone are broadly used in the treatment of both solid and
hematologic malignancies [3,9,10], but are limited in part by their
sensitivity to P-glycoprotein (P-gp) receptor-mediated efflux
[12,13,14].
In addition to intercalation and topoisomerase II poisoning, the
anthracyclines interact with DNA in multiple ways, mediating
DNA damage through non topoisomerase II-mediated mecha-
nisms [15–16]. Principal scaffold-related cytotoxic activities of
these drugs arise from induction of reactive oxygen species (ROS)
that generate mutagenic base modifications with minimal site
selectivity [17,18]. ROS also stimulate cellular formaldehyde
production, which in turn drives the formation of anthracycline
DNA adducts and crosslinks [16,19,20,21,22,23]. The relative
roles of each of these processes in the clinical activity and toxicity
of the compounds remains in debate [11,15,16]. The generation of
ROS has been associated with the induction of cardiomyopathy
which limits the lifetime cumulative anthracycline dose
[15,24,25,26]. In addition, oxidative DNA base damage that
induces potentially mutagenic lesions was observed in blood
samples from doxorubicin-treated patients [18]. These limitations,
combined with susceptibility to P-gp-mediated drug resistance,
have prompted the search both for third-generation anthracyclines
and for alternatives to the anthracycline scaffold [11], to avoid
such liabilities while retaining the efficacy of these broadly used
drugs [16,27,28].
Quinolone-based drugs induce DNA damage in bacteria by
poisoning bacterial DNA gyrase and topoisomerase IV, enzymes
that are functional analogs of eukaryotic topoisomerase II
[29,30,31,32]. This led Tomita and coworkers to screen a number
of antibacterial agents with quinolone-type ring structures for
possible antineoplastic activity [33]. A class of compounds bearing
a 1,8-naphthyridine core was subsequently optimized for cytotox-
icity [34], resulting in the discovery of voreloxin (AG-7352), a
novel naphthyridine analog (Figure 1). Voreloxin has no
antibacterial activity, but exhibits potent cytotoxicity towards
eukaryotic cancer cell lines [35], synergistic activity with
cytarabine in acute myeloid leukemia (AML) cancer cell lines
and supra-additivity in combination with cytarabine in a mouse
model of bone marrow ablation and recovery [36]. Voreloxin
activity was not affected by common mechanisms of drug
resistance, including P-gp overexpression, when evaluated in
etoposide- and anthracycline-resistant nonclinical models. These
data, including cell-based and in vivo activity in 3 drug resistant
cell lines, are previously published by Hoch et al [35]. In addition,
objective responses were observed in patients for whom prior
treatment with anthracyclines has failed [37,38].
Here we establish the activity of voreloxin as a first-in-class
topoisomerase II poison and inhibitor that intercalates DNA and
induces site-selective DNA DSB, G2 arrest, and apoptosis. Using
planar and nonplanar analogs, we determined that the inter-
calative properties of voreloxin are critical for its anticancer
activities. In defining the voreloxin mechanism of action, these
studies identify a novel chemical scaffold, distinct from the
anthracyclines and epipodophyllotoxins, for development of
topoisomerase II poisons that avoids resistance due to P-gp
expression and possibly also the dose-limiting toxicities of the
anthracyclines.
Results
Voreloxin is a topoisomerase II poison and induces site-
selective DNA DSB mediated by human topoisomerase
IIa and b
The ability of voreloxin to poison human topoisomerase II was
evaluated in CCRF-CEM acute lymphocytic leukemia cells using
the ICE bioassay [39]. This assay evaluates the amount of
topoisomerase II stably associated with DNA (i.e., identifies the
generation of stable cleavage complexes) by means of DNA
isolation followed by immunoblot for detection of associated
enzyme. As shown in Figure 2A, no cleavage complexes were
detected after exposure to 0.1 mM voreloxin. One mM voreloxin
Figure 1. Voreloxin is a quinolone derivative. The chemical structures of voreloxin, ciprofloxacin and doxorubicin are shown. The core
naphthyridine, quinolone, and anthracycline components are circled. Similarities between the core of the naphthyridine and quinolone are evident,
as is the chemical dissimilarity between these two classes of compounds and the anthracyclines.
doi:10.1371/journal.pone.0010186.g001
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and b, with only a slight increase in cleavage complex formation at
20 mM. Densitometry readings indicated that the levels of cleavage
complex induced by 1 mM voreloxin were equivalent to
approximately one-half of those induced by 1 mM etoposide, and
were comparable with those induced by 1 mM doxorubicin.
The induction of DNA DSB by voreloxin was established by
pulsed-field gel electrophoresis following treatment of CCRF-CEM
cells with a dose-titration of voreloxin. Dose-dependent induction of
DNA fragmentation was detectable at the lowest (0.3 mM) concen-
tration employed (Figure S1). In comparison with 0.1 mM doxoru-
bicin, 1 mM voreloxin induced approximately equivalent DNA DSB.
The quinolone antibacterials interact with DNA and bacterial
DNA gyrase and topoisomerase IV to induce DSB at preferred
sequences [40]. To determine whether voreloxin recapitulates
such activity, plasmid DNA was incubated with human topoisom-
erase IIa or b in the presence of a dose-titration of voreloxin, and
reaction products were analyzed by gel electrophoresis. As shown
in Figure 2B, dose-dependent fragmentation of DNA was observed
with the production of a specific DNA fragment at all doses, in
contrast with the DNA laddering induced by 1 mM etoposide.
The voreloxin cleavage product was quantified by densitometry
and found to peak at voreloxin concentrations of 0.5 mM
(topoisomerase IIa)o r1mM (topoisomerase IIb) and decline at
higher concentrations, suggesting inhibition of enzymatic activity
by higher drug concentrations (Figure S2). This may result from
catalytic inhibition or, possibly, by limiting access of topoisomerase
II to DNA as the amount of intercalated drug increases. These
possibilities are currently under investigation. Sequencing of the
specific cleavage fragment identified the cleavage site as GC/GG
(Figure S2). This is consistent with the preferred cleavage site of
quinolones, which induce DNA cleavage at and around G/C rich
sequences [40] and in contrast with the topoisomerase II-mediated
DNA DSB induced by doxorubicin, which favors a 39A at the site
of cleavage [41].
Voreloxin-induced G2 arrest is partially dependent on
topoisomerase II
The dependence of voreloxin on topoisomerase II for G2 arrest,
a hallmark of topoisomerase II inhibition [42], was investigated in
the A549 lung cancer cell line using siRNA knockdown of
topoisomerase IIa (the isoform associated with replication and
essential for chromosome segregation). The level of knockdown
shown in Figure 3A is representative of 6 experiments performed
using this approach. The extent of topoisomerase IIa knockdown
was maximal at 48 h, at which time the cells were treated with
titrated amounts of voreloxin for 16 h. The relatively short
duration of this assay allowed analysis to be completed within the
timeframe of a transient topoisomerase IIa knockdown. Cells with
reduced topoisomerase IIa showed reduced sensitivity to vor-
eloxin-induced G2 arrest. Maximal arrest was observed at 1 mMi n
the cells with reduced levels of topoisomerase IIa (47% of cells in
G2) whereas 0.11 mM voreloxin in the control cells achieved
comparable arrest (40% of cells in G2) and was maximal at
0.33 mM (59% of cells in G2) (Figure 3A, histograms of complete
dose-range are shown in Figure S3a and a summary of additional
experiments is shown in Table S1).
The effect of reduced topoisomerase IIa expression on
voreloxin-induced G2 arrest was compared with the effect on
doxorubicin- and etoposide-induced G2 arrests in the same
transfected cell population (Figure 3B, raw histograms in Figure
S3b and Figure S3c, respectively, and a summary of data from
additional experiments is shown in Table S2). When topoisom-
erase IIa levels were reduced, the induction of G2 arrest in
doxorubicin-treated cells shifted from a maximum at 0.037 mMi n
control cells (57% of cells in G2) to 0.33 mM (53% of cells in G2).
Thus, the magnitude of desensitization to drug-induced G2 arrest
by topoisomerase IIa knockdown was comparable for voreloxin
and doxorubicin. Etoposide activity was more dependent upon
topoisomerase IIa expression (Figure 3B). The G2 arrest (53% of
cells in G2) was evident at 0.33 mM in control cells whereas a
Figure 2. Voreloxin poisons topoisomerase II and induces site-selective DNA DSB. A, CCRF-CEM cells were untreated (No drug) or treated
for 4 h with voreloxin (0.1–20 mM), doxorubicin (1 mM) or etoposide (1 or 10 mM), DNA harvested through a caesium chloride pad, DNA quantities
normalized, and topoisomerase II levels analyzed following a slot blot using anti-topoisomerase IIa or b antibodies. The immunoblot is a
representative of three independent experiments. Quantitative analysis was performed using the Alpha Innotech digital imaging system and each
condition was compared relative to the level of cleavage complex induced by 1 mM etoposide. Error bars represent the standard deviations for three
independent experiments. B, pBR322 was incubated in vitro with either purified topoisomerase IIa or b and a dose-titration of voreloxin (0.1–10 mM)
or etoposide (5 mM). DNA cleavage was assessed using SDS-PAGE, with untreated reaction mix (0) or DNA alone (DNA) as controls. Densitometry
quantification of the indicated band, and the sequence surrounding the cleavage site, are shown in Figure S2.
doi:10.1371/journal.pone.0010186.g002
Novel Topoisomerase II Poison
PLoS ONE | www.plosone.org 3 April 2010 | Volume 5 | Issue 4 | e10186Novel Topoisomerase II Poison
PLoS ONE | www.plosone.org 4 April 2010 | Volume 5 | Issue 4 | e10186lower level of arrest (38% of cells in G2) was evident only at 3 mM
etoposide in topoisomerase IIa knockdown cells.
Voreloxin does not generate significant levels of ROS
Because ROS contribute to the DNA damage induced by the
anthracyclines, the production of ROS by voreloxin was
investigated and compared with that of doxorubicin. HCT-116
colon cancer cells were treated for 6 h with a dose-titration of
either voreloxin (1–9 mM) or doxorubicin (0.03–2 mM) in the
presence of a ROS indicator (29,79- dichlorofluorescein which
fluoresces when oxidized). As shown in Figure S4, voreloxin did
not produce significant levels of ROS in comparison with
doxorubicin. These observations are consistent with voreloxin’s
less chemically reactive quinolone-based structure [29].
Voreloxin cytotoxic activity requires DNA intercalation
Structure-activity studies of 1,8-naphthyridine analogs suggested
that coplanarity of the naphthyridine core and the N-1 thiazole
ring was required for antineoplastic activity. In earlier studies of
voreloxin analogs, replacing the thiazole ring with a phenyl ring
led to a 100-fold reduction in activity [33]. Based on electronic
structure analysis, we attributed this loss in activity to the need for
the phenyl ring to twist out-of-plane to avoid steric conflicts. The
relationship of molecular planarity to intercalation potential was
probed using two structural analogs of voreloxin (Figure 4A). The
N-1 phenyl compound was synthesized as a nonplanar compar-
ator, while a fused analog was generated to enforce planarity of the
aromatic system. The intercalative properties of the three
compounds were evaluated in a topoisomerase I intercalation
assay, using either negatively supercoiled or relaxed DNA as the
substrate. As shown in Figure 4B and 4C, voreloxin intercalation
of DNA was detectable at 1 mM, and at 10 mM full intercalation
was observed. No intercalation of the phenyl derivative was
identified, whereas the fused phenyl analog intercalated DNA to a
greater extent than voreloxin, and was maximal by 5 mM.
To correlate cytotoxicity with the intercalative potential of
voreloxin and the structural analogs, their activities were
compared in both proliferation (Figure 5) and colony forming
assays (Figure S5). No IC50 could be established for the
nonintercalative phenyl derivative, due to weak and absent
cytotoxicity in the proliferation and colony growth inhibition
assays, respectively (Figure 5 and Figure S5). In contrast, the
intercalative fused phenyl analog was consistently more cytotoxic
than voreloxin in both proliferation and colony growth inhibition
assays (Figure 5 and Figure S5). A comparison of the inhibition of
proliferation by the two compounds showed an average 9.5-fold
increase in potency over voreloxin for the planar fused phenyl
intercalative analog (Figure 5). These data are representative of
proliferation inhibition data obtained in three additional human
cancer cell lines: HCT-116 and HT-29 (colon cancer) and K562
(chronic myelocytic leukemia).
No G2 arrest was observed with the phenyl nonintercalative
analog (Figure S6 and Table S3). Dose-dependent induction of G2
arrest by the planar fused phenyl intercalative analog was
established, and the effect of topoisomerase IIa knockdown on
the induction of G2 arrest was compared with voreloxin in the
same population of siRNA transfected cells. Desensitization to
voreloxin consistent with previous data, as well as with the planar
fused phenyl analog, was observed in cells with reduced levels of
topoisomerase IIa (Figure 6, raw histograms in Figure S6). The
planar fused phenyl analog induced G2 arrest in control cells at
0.11 mM (48% of cells in G2) and at 0.33 mM (40% of cells in G2)
in topoisomerase IIa knockdown cells. Consistent with the
enhanced cytotoxicity of this analog, a greater percentage of
sub-G1 cells was identified at $1 mM, regardless of topoisomerase
IIa knockdown (Figure S6). Repeats of this analysis are shown in
Table S3. These data suggest that the cytotoxicity of the fused
phenyl analog is less dependent than voreloxin upon topoisom-
erase II expression, and that enhanced intercalation has a greater
impact on DNA structure and processing.
Discussion
Voreloxin is a first-in-class quinolone derivative currently
completing Phase 2 clinical trials in AML and platinum-resistant
ovarian cancer. Here we establish that voreloxin intercalates DNA
and poisons topoisomerase II, inducing site-selective DNA DSB
and G2 arrest. The structures of voreloxin and the prototype
fluoroquinolone antibacterial, ciprofloxacin, are illustrated in
Figure 1. We used this structural similarity to help frame further
mechanistic studies of voreloxin, and to guide comparison with
other classes of antineoplastic agents in clinical use that cause
DNA damage by interfering with topoisomerase II function.
The peak in voreloxin-induced DNA fragmentation at 1 mM,
declining at higher concentrations, is consistent with the bell-
shaped curve of DNA cleavage seen with intercalative topoisom-
erase II poisons [43,44] and demonstrates that, although voreloxin
retains many of the structural features of the quinolones, it has
enhanced ability to intercalate double-stranded DNA [30,45]. The
peak in formation of cleavage complexes at approximately 1 mM
voreloxin is in keeping with the observed concentration range for
saturation in the DNA fragmentation and intercalation assays and
represents the plasma concentration maintained for over 24 hours
in treated patients [38]. The concomitant loss of cytotoxicity and
intercalation in the phenyl voreloxin analog, and the increased
cytotoxicity of the more intercalative fused phenyl analog, suggests
the requirement for intercalation for anticancer cell cytotoxicity of
quinolone analogs. In addition, topoisomerase IIa knockdown had
a greater impact on the ability of etoposide (nonintercalative) to
induce G2 arrest than on the G2 arrest activities of voreloxin, the
planar fused phenyl analog, or doxorubicin. The impact of
enhanced intercalation on molecular mechanism, which manifest-
ed in more potent cytotoxicity and reduced topoisomerase II
dependence, is under investigation.
Because of similarities in mechanism of action, specifically both
DNA intercalation and topoisomerase II poisoning, the anthracy-
clines are effective to help guide indication selection for voreloxin
[15,16]. In combination with cytarabine (the ‘‘7+3’’ treatment
schedule), the anthracyclines are the standard of care in the
Figure 3. Topoisomerase II knockdown has a greater effect on G2 arrest induced by etoposide than by voreloxin or doxorubicin. A,
A549 cells were transfected with siRNA targeting topoisomerase IIa (Topo IIa KD), or with scrambled control siRNA for 48 h, when a sample was taken
to confirm the knockdown by Western blot. Blank = no siRNA. At 48 h, cells were treated for 16 h with a dose-titration (0.001–3 mM) of voreloxin and
stained with BrdU followed by flow cytometry analysis. The percentages of cells in the G2 phase of the cell cycle, calculated from these data, are
represented by the line graphs. Data are representative of 6 independent experiments. B, Cells were transfected and treated as described in (A) with a
dose-titration (0.001–3 mM) of voreloxin, doxorubicin or etoposide. The same total transfected cell population was split and seeded for treatment
with each drug. The percentages of cells in the G2 phase of the cell cycle are represented by the line graphs. Histograms are shown in Figure S3a,
S3b, S3c. Data were consistent in 2 independent experiments.
doi:10.1371/journal.pone.0010186.g003
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treatment of other hematologic malignancies, as well as for breast
and ovarian cancers [25]. Despite the efficacy of anthracycline-
based therapies, structure-based toxicities limit their use, partic-
ularly given the cardiomyopathy that is associated with cumulative
dose [15,16,25,26]. The generation of ROS has been linked to the
cardiotoxicity of the drugs [15] and also has been shown to induce
potentially mutagenic DNA base lesions [18] in addition to driving
the generation of DNA adducts and crosslinks [16,19,20]. In
contrast, the quinolone core of voreloxin is less chemically
reactive. As reported here, voreloxin does not generate significant
ROS in cell-based studies, and the formation of ROS or DNA
alkylation are not associated with the activity of the core quinolone
structure. Dose-limiting toxicities of voreloxin are reversible oral
mucositis (AML) [46,47] and neutropenia (solid tumors) [37]. The
contrasting structures of voreloxin and the anthracycline family
member, doxorubicin, are shown in Figure 1.
The ability to induce site-selective DNA damage at GC/GG
regions distinguishes voreloxin from both the anthracyclines and
etoposide. By analogy with the quinolones, this may reflect a
consequence of sequence-selective DNA cleavage by topoisomer-
ase II in the context of the drug/DNA/enzyme complex [40,45].
These targeted DNA-enzyme interactions contrast with the
mechanistically less targeted [11,15,16,18,19,20,21,22,23] and
highly intercalative [48] anthracyclines in current clinical use.
The ability of voreloxin to intercalate double-stranded DNA in the
absence of topoisomerase II suggests that the intercalative
properties of the molecule are greater than those of the quinolone
antibacterials [29,30,45].
Efficacy of both the anthracyclines and etoposide is hampered
by sensitivity to the common tumor resistance mechanism of P-gp
efflux [12,13,14]. In contrast, voreloxin is not a P-gp substrate [35]
and has potent activity in nonclinical models of anthracycline- and
etoposide-resistance that include overexpression of P-gp [35]. In
addition, voreloxin was active against primary tumor biopsies
resistant to doxorubicin or etoposide or both, and objective
responses were observed in patients with relapsed/refractory AML
and platinum-resistant ovarian cancer for whom anthracycline-
based therapies have failed [37,38].
The identification of the quinolone scaffold as a source for novel
topoisomerase II poisons, combined with recent progress in our
understanding of topoisomerase II biology, structure and function
[5,11,49], provides a rationale to further examine this new family
of anticancer therapeutics. For example, exploring topoisomerase
Figure 4. Voreloxin and the fused phenyl analog intercalate DNA, while the nonplanar phenyl analog does not. A, Structures of
voreloxin and the two analogs are shown, with the thiazole group of voreloxin boxed and the fused phenyl and phenyl rings highlighted by arrow or
box, respectively. B and C, Agarose gels stained with ethidium bromide are shown. Intercalation was evaluated by conversion of negatively
supercoiled DNA (-SC) into positively supercoiled DNA (+SC) (4B) or the conversion of relaxed plasmid DNA (Rel) to supercoiled molecules (SC) (4C).
Control reactions were carried out in the absence of both drug and enzyme (labeled as DNA) or in the absence of drug but containing enzyme
(labeled 0). Topoisomerase I concentration was constant. Reactions containing etoposide (100 mM) and ethidium bromide (10 mM) are included as
examples of a nonintercalative and intercalative drug, respectively. Data were consistent in two independent experiments.
doi:10.1371/journal.pone.0010186.g004
Figure 5. Cytotoxicity correlates with the ability of voreloxin and analogs to intercalate DNA. A549 cells were treated for 72 h with a
dose-titration (0.0001–10 mM) of voreloxin or analog, each treatment point performed in triplicate, N=2, and the inhibition of proliferation analyzed
by MTT assay. Error bars represent standard error of the mean (SEM) for the two independent experiments. The potency of the analogs relative to
voreloxin was compared using IC50 values. The compound structures are inset, with the fused phenyl and phenyl rings highlighted by arrow or box,
respectively.
doi:10.1371/journal.pone.0010186.g005
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topoisomerase II mutants to voreloxin and analogs, and possibly
mapping the sites of drug–enzyme interaction may allow further
optimization of topoisomerase II-targeting therapeutics to enhance
clinical benefit.
In summary, these data establish voreloxin as a first-in-class
quinolone analog that exerts potent anticancer activity through a
mechanism that parallels the activity of the quinolones in bacterial
cells, namely interaction withDNAand topoisomerase II poisoning.
Voreloxin displays increased intercalation into double-stranded
DNA compared to the antibacterials, and topoisomerase II
poisoning that induces site-selective DNA DSB in GC rich regions.
Based upon both chemical and mechanistic differences reported
here, voreloxin may provide clinical advantages over other
topoisomerase II poisons that are currently in use. Continued
interrogation of the molecular and cellular activities of voreloxin
and other members of this new family of quinolone derivatives as
potential anticancer therapeutics is the focus of ongoing research.
Materials and Methods
Enzymes and materials
Recombinant wild-type human topoisomerase IIa and IIb were
expressed in Saccharomyces cerevisiae and purified as described
previously[50]. Negatively supercoiled pBR322 DNA was pre-
pared from Escherichia coli using a Plasmid Mega Kit (Qiagen) as
described by the manufacturer.
Formation of topoisomerase II-DNA cleavage complexes
in cultured human cells
Human CEM leukemia cells were cultured under 5% CO2 at
37uC in RPMI 1640 medium (Cellgro by Mediatech, Inc.),
containing 10% heat-inactivated bovine calf serum (Hyclone) and
2 mM glutamine (Cellgro by Mediatech, Inc.). The in vivo
complex of enzyme (ICE) bioassay was modified as noted on the
TopoGen, Inc. web site and detailed in Methods S1 [51,52].
Site-specific DNA cleavage mediated by topoisomerase II
DNA cleavage sites were mapped using a modification of the
procedure of O’Reilly and Kreuzer [53] as detailed in Methods S1.
DNA intercalation
Intercalation reaction mixtures contained 16.5 nM topoisom-
erase I and 5 nM relaxed or negatively supercoiled pBR322 DNA
in a total of 20 mL of 50 mM Tris-HCl (pH 7.9), 0.1 mM EDTA,
50 mM KCl, 10 mM MgCl2, 0.5 mM DTT and 30 mg/mL BSA
that contained 0–15 mM voreloxin or analogs. Mixtures were
incubated at 37uC for 6 min, extracted with phenol:chloroform:i-
soamyl alcohol (25:24:1), and added to 3 mL of 0.77% SDS,
77 mM EDTA (pH 8.0). Samples were mixed with 2 mLo f
agarose gel loading buffer, heated at 45uC for 5 min, and
subjected to electrophoresis in a 1% agarose gel in 100 mM Tris-
borate (pH 8.3), 2 mM EDTA. Gels were stained with 1 mg/mL
ethidium bromide, and DNA bands were visualized by ultraviolet
light using an Alpha Innotech digital imaging system. Interpreta-
tion of these data are further explained in Methods S1.
Cell cycle analysis
A549 cells were treated with 0.001–3 mM drug diluted in RPMI
1640 growth media containing 10% fetal calf serum for 16 h.
Following treatment, adherent and floating cells were harvested,
washed with PBS, fixed and stained for total DNA content based
on propidium iodide fluorescence and cell cycle analysis
performed by FACS as described in Methods S1.
siRNA knockdown
A549 cells were transfected with 75 nM topoisomerase IIa-
targeting siRNA (Dharmacon (Thermo Scientific) TOP2A ON-
TARGETplus SMARTpool # L-004239-00-0005) combined with
Lipofectamine 2000 (Invitrogen) in RPMI 1640 growth media
containing 10% fetal calf serum, as recommended by the
manufacturers. Additional control samples included cells trans-
fected with nontargeting siRNA (Dharmacon (Thermo Scientific)
ON-TARGETplus Non-targeting Pool # D-001810-10-05) and
cells treated with Lipofectamine 2000 alone. After 24 h, cells were
harvested with 0.1% trypsin-EDTA and seeded in 12-well dishes
at 50,000 cells/well in normal growth media. Following an
additional 24 h of growth (48 h following the initial exposure to
siRNA), cells were treated with a dose-titration of voreloxin,
doxorubicin, etoposide, or voreloxin analog.
Western blot
Cells from each of the transfection conditions were harvested,
lysed in M-PER buffer (Pierce), and topoisomerase IIa protein
levels determined by Western blot analysis using a topoisomerase
IIa specific antibody (Abcam) as described in Methods S1. Beta-
actin was used as normalizing control.
Measurement of cell proliferation by MTT
Cells were plated in 96-well plates at 1000 cells/well and treated
with compound or vehicle control (0.1% final concentration) for
Figure 6. Topoisomerase IIa knockdown reduces the G2 arrest induced by the planar voreloxin analog. A549 cells were transfected
with siRNA targeting topoisomerase IIa (Topo IIa KD), or with scrambled control siRNA, for 48 h. At 48 h, cells were treated for 16 h with a dose-
titration (0.037–3 mM) of voreloxin or analog and stained with BrdU followed by flow cytometry analysis. Histograms are shown in Figure S6. The
percentages of cells in the G2 phase of the cell cycle were calculated and are represented in the line graphs. No G2 arrest was observed with the
nonintercalative analog (Figure S6 and Table S3). Data are representative of three independent experiments.
doi:10.1371/journal.pone.0010186.g006
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(5 mg/mL, Sigma-Aldrich) was added directly to the media and
incubated at 37uC/5% CO2 for 2 h. MTT lysis buffer was added
and cells were incubated at 37uC/5% CO2 overnight. Samples
were analyzed by measuring the light absorbance at 595 nm using
the SpectraMax plate reader (Molecular Devices). Values obtained
for treatment samples were normalized to control samples.
Supporting Information
Figure S1 CCRF-CEM cells were treated for 6 h with a dose-
titration of voreloxin (0.3 - 9 mM), 0.1 mM doxorubicin, or vehicle
control, harvested and analyzed by PFGE. Fragmented DNA is
detectable as indicated. MW = molecular weight marker. 0=
untreated cells. Veh = vehicle.
Found at: doi:10.1371/journal.pone.0010186.s001 (2.57 MB
TIF)
Figure S2 Densitometry analysis and sequence determination of
specific voreloxin cleavagae product (identified in Figure 2B). The
sequencing image is a representative of three independent
experiments. The quantitative analysis of the indicated voreloxin
cleavage product is shown relative to untreated control using the
Bio Rad Molecular Imager FX and the error bars represent three
independent experiments. Sequencing of this product identified
the site-selective cleavage sequence shown above the cleavage
complex bar graph.
Found at: doi:10.1371/journal.pone.0010186.s002 (0.42 MB
TIF)
Figure S3 Histograms showing the effect of voreloxin, doxoru-
bicin or etoposide on G2 arrest, in control cells or cells with
reduced topoisomerase IIa. A549 cells were transfected with
siRNA targeting topoisomerase IIa or with scrambled control
siRNA for 48 h, when they were treated for 16 h with a dose-
titration (0.001–3 mM) of (a) voreloxin, (b) doxorubicin, or (c)
etoposide and stained with BrdU followed by flow cytometry
analysis.
Found at: doi:10.1371/journal.pone.0010186.s003 (2.73 MB
TIF)
Figure S4 Comparison of ROS generation by voreloxin and
doxorubicin. a. HCT116 cells were treated for 6 hours with a
dose-titration of voreloxin (0.3–3 mM, upper panel), doxorubicin
(0.1–1 mM, lower panel), or vehicle only negative control, in the
presence of 29,79-dichlorofluorescein (DCF). ROS production was
evaluated by FACS detection of oxidized fluorescent DCF reagent,
comparing unstained cells (background fluorescence) with treated
cells, counting 5000 events per treatment. b. Cells were treated as
in (a) with voreloxin (1–9 mM), doxorubicin (2 mM), hydrogen
peroxide positive control (H202 at 400 mM) or vehicle only
negative control. ROS production was evaluated as in (a).
Found at: doi:10.1371/journal.pone.0010186.s004 (8.05 MB TIF)
Figure S5 Colony growth inhibition induced by voreloxin and
analogs. A549 cells were treated for 24 h with a dose-titration
(0.03–3 mM) of voreloxin or analog, with each treatment point
performed in triplicate. Cells were washed and seeded for analysis
of colony growth inhibition as described. Data represent colonies
detectable following 5 days growth, N=2. Error bars represent
SEM of the two independent experiments.
Found at: doi:10.1371/journal.pone.0010186.s005 (0.88 MB TIF)
Figure S6 Histograms showing the effect of voreloxin or analogs
on G2 arrest in control cells or cells with reduced topoisomerase
IIa. A549 cells were transfected with siRNA targeting topoisom-
erase IIa or with scrambled control siRNA for 48 h, when they
were treated for 16 h with a dose-titration (0.037–3 mM) of
voreloxin or analogs.
Found at: doi:10.1371/journal.pone.0010186.s006 (1.64 MB TIF)
Table S1 Summary of additional five experiments investigating
the effect of topoisomerase IIa knockdown on voreloxin-induced
G2 arrest. Indicated for each treatment group are the drug
concentrations at which maximal G2 arrest was observed, and the
percentage of cells in G2 at maximal arrest for each treatment
group. Each experiment was performed independently.
Found at: doi:10.1371/journal.pone.0010186.s007 (0.12 MB PPT)
Table S2 Summary of additional two experiments investigating
the effect of topoisomerase IIa knockdown on doxorubicin and
etoposide-induced G2 arrests. Indicated for each treatment group
are the drug concentrations at which maximal G2 arrest was
observed, and the percentage of cells in G2 at maximal arrest
for each treatment group. Each experiment was performed
independently.
Found at: doi:10.1371/journal.pone.0010186.s008 (0.12 MB PPT)
Table S3 Summary of additional two experiments investigating
the effect of topoisomerase IIa knockdown on the planar analog
and phenyl analog-induced G2 arrests. Indicated for each
treatment group are the drug concentrations at which maximal
G2 arrest was observed, and the percentage of cells in G2 at
maximal arrest for each treatment group. Each experiment was
performed independently.
Found at: doi:10.1371/journal.pone.0010186.s009 (0.12 MB PPT)
Methods S1
Found at: doi:10.1371/journal.pone.0010186.s010 (0.04 MB
DOC)
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